Boston, May 16, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leader in hybrid care enablement, today announced its Co-CEO and President, Roy Schoenberg, M.D., M.P.H., will speak at the Disability & Telehealth Conference at 12:15 PST on Saturday, May 18. The virtual conference explores barriers to telehealth enhancement for those with disabilities and the innovative solutions underway to advance healthcare accessibility.
Schoenberg will participate in the virtual panel, “Technology and Bold Solutions for Accessible Telehealth.” The session will focus on big tech’s role in driving innovations to meet the unique needs of patients with disabilities and will highlight the strategies and approaches that can fill care and accessibility gaps and improve health equity. Schoenberg will be joined by leaders from Stanford Medicine, Stanford Health Care, Zoom and Apple.
“The one in four adults in the U.S. who live with a disability that prevents them from accessing healthcare deserve better from the industry that is essential for their vitality,” said Schoenberg. “Virtual care is a bridge that can connect individuals to the care they need, helping to overcome physical, societal, and communication barriers and a lack of accessible medical equipment or transportation. I’m glad to represent Amwell in this important conversation that’s increasing prioritization for healthcare to become more equitable and inclusive for all.”
Amwell solutions prioritize improving access to quality healthcare for everyone, including those with disabilities. Patients can access care from anywhere with standard cellular coverage or internet connection, reducing the need to travel to in-person appointments and check-ins. Language and communication barriers are addressed with Interpreter Services and accessibility features enabled on Amwell Converge™, a WCAG-conformant platform.
To learn more and register for the Disability & Telehealth Conference, click here.
About Amwell
Amwell is a leading hybrid care enablement platform in the United States and globally, connecting and enabling providers, payers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that hybrid care delivery will transform healthcare. We offer a single, comprehensive platform to support all digital health needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With nearly two decades of experience, Amwell powers the digital care of more than 50 health plans, which collectively represent more than 100 million covered lives, and many of the nation’s largest health systems. For more information, please visit https://business.amwell.com/.
©2024 American Well Corporation. All rights reserved. Amwell®, SilverCloud®, ConvergeTM, CarepointTM and the Amwell Logo are registered trademarks or trademarks of American Well Corporation.
Last Trade: | US$7.87 |
Daily Change: | 0.03 0.38 |
Daily Volume: | 77,920 |
Market Cap: | US$107.580M |
December 18, 2024 October 30, 2024 October 08, 2024 July 31, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB